Work

Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.6_suppl.472

Authors: Elio Adib, Rohit K. Jain, William Paul Skelton, Dory Freeman, Catherine Curran, Elie W. Akl, Amin Nassar, Praful Ravi, Charlene Mantia, Jaime R. Merchan, Winston Tan, Trisha M. Plastini, Toni K. Choueiri, Guru Sonpavde

Institutions: Dana-Farber Cancer Institute, Moffitt Cancer Center, Brigham and Women's Hospital, University of Miami, Mayo Clinic in Florida, University of Pennsylvania Health System, Harvard University, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3133570249

Cites:

Cited by: 4

Related to: 10